Cooper Companies Inc

Cooper Companies Inc(COO)股票分析

$58.970

-0.147 (-0.25%)收盘时

Loading chart…
最高
59.380
开盘
58.670
成交量加权均价
58.93
成交量
2.15M
市值
17.45B
最低
58.425
成交额
126.96M
企业价值/息税折旧摊销前利润(TTM)
10.47

The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee.

AI 分析 of Cooper Companies Inc (COO)

买入

Cooper Companies Inc is a good buy right now due to its recent performance and insider confidence. The current price is $57.94, and the RSI is at 70.129, indicating strong momentum. Additionally, the forward P/E ratio is 11.34, suggesting the stock is undervalued compared to its earnings potential. However, there is a risk of a potential decline in revenue growth, with expectations of only 0% to 2% growth for the fourth quarter.

分析师评级(15)

上行空间 +53.18%
买入
10 买入
5 持有
0 卖出
当前: 58.97
最低
73.00
平均
90.33
最高
100.00

Barclays

2026-10-06

目标价

$60

Equal Weight

Mizuho

2026-09-11

目标价

$75

跑赢大盘

JPMorgan

2026-09-10

目标价

$58

中性

Needham

2026-09-10

目标价

$73

买入

Citi

2026-09-10

目标价

$60

中性

估值指标

Cooper Companies Inc(COO)当前预期市盈率为 11.34,5 年平均预期市盈率为 22.79。

预期市盈率

严重低估
5 年均值 P/E
22.79
当前P/E
11.34
高估
27.98
低估
17.60

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
19.25
当前EV/EBITDA
10.47
高估
45.86
低估
-7.36

预期市销率

低估
5 年均值 P/S
4.36
当前P/S
2.55
高估
5.30
低估
3.42

Alphio AI 对 COO 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%COO

$100.88

情景价格

基

基准

基准 · 50%COO

$92.29

情景价格

悲

悲观

悲观 · 25%COO

$83.71

情景价格

持有 COO 的大户

T

Trajan Wealth, L.L.C.

+ 持有COO

+9.30%

3个月收益率

M

Manning & Napier Advisors, LLC

+ 持有COO

+6.49%

3个月收益率

H

Heartland Advisors, Inc.

+ 持有COO

+1.11%

3个月收益率

D

Diamond Hill Capital Management, LLC

+ 持有COO

+0.42%

3个月收益率

T

Triodos Investment Management B.V.

+ 持有COO

-0.52%

3个月收益率

F

Findlay Park Partners LLP

+ 持有COO

-5.11%

3个月收益率

COO 常见问题 —— 由 Alphio AI 解答

The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee. It operates in the Healthcare sector (OPHTHALMIC GOODS industry).

Cooper Companies Inc is a good buy right now due to its recent performance and insider confidence. The current price is $57.94, and the RSI is at 70.129, indicating strong momentum. Additionally, the forward P/E ratio is 11.34, suggesting the stock is undervalued compared to its earnings potential. However, there is a risk of a potential decline in revenue growth, with expectations of only 0% to 2% growth for the fourth quarter.

15 analysts cover COO: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 90.33.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易